Core Competitiveness - The company has established a complete industrial chain for ibuprofen, from key intermediates to active pharmaceutical ingredients (APIs) and finished dosage forms, with an API annual production capacity accounting for nearly 40% of global total capacity, making it the largest single production base globally [1][2] - Founded in 1943, the company has evolved into a leader in the field of antipyretic and analgesic drugs, with an annual production capacity of 50,000 tons for chemical APIs, 500,000 tons for intermediates, 32 billion solid dosage forms, and 1.5 billion injection doses [1] Industry Leadership in Ibuprofen - The company has built an integrated strategy of "API + formulation," with a domestic market share of 45.14% in 2022 and export volume accounting for two-thirds of its annual production [2] - The ibuprofen API has received EU COS certification and passed FDA certification, reinforcing its position in the global market [2] Technological Innovation - Continuous breakthroughs in technology have led to the development of new synthetic processes, which won the first prize in the Shandong Provincial Science and Technology Progress Award in 2023, reducing reaction time by 40% and lowering energy consumption by 25% compared to industry averages [4] - The company holds 13 invention patents, establishing technological barriers, including customized crystal form control technology to produce special particle size products based on different dosage form requirements [4] Quality Control Standards - The company implements stringent internal control standards that exceed pharmacopoeia requirements, with impurity limits for ibuprofen set at 0.05% compared to the USP standard of 0.3% [5] - The entire production system complies with GMP standards in China, Europe, and the US, making the company a core supplier for major ibuprofen formulation manufacturers [5] Product Line Expansion - The company is expanding its formulation product line, with plans to launch ibuprofen suspension in 2023, sustained-release capsules in 2024, and other formulations by 2025, covering a full lifecycle dosage form matrix [5] - The company is pursuing dual-track strategies in the domestic market through national procurement and refined retail terminal招商, while also expanding into international markets [5] Research and Development Focus - Since the "14th Five-Year Plan," the company has focused on key areas such as cardiovascular, digestive system, and anti-tumor drugs, increasing R&D investment and achieving significant progress in innovative drugs [8] - The company has obtained 81 drug registration approvals, 27 consistency evaluation approvals for generic drugs, and 40 authorized invention patents [8] New Business Ventures - The company is actively advancing its "Internet + health" strategy, collaborating with JD.com and local health authorities to build a medical information platform and offering a one-stop internet healthcare solution [9] - It has launched high-purity fish oil health products and is entering the functional health beverage market with a new vitamin energy drink [9]